Nkarta Inc

NKTX exhibits a clear sequence of higher highs and higher lows within a Stage 2 advance, with price accepting pullbacks into rising EMAs and reclaiming support. The medium-term structure remains bullish, reinforced by our Speculative strategy’s preference for continuation setups. Short-term timing is favorable as price tracks above the 9/20 EMAs and rebounds from recent consolidation. We recommend engaging now on a pullback interaction around the EMA zone, targeting continuation of the established uptrend.

• ↑Holds $243.2M in cash, supporting R&D through 2029
• ↑Enrolling patients in NKX019 Ntrust-1/2 trials with expected early data
• ↓Q2 2026 net loss of $40.4M ($0.54/sh) highlights steep losses